Literature DB >> 28430034

UM-Chor1: establishment and characterization of the first validated clival chordoma cell line.

John Henry Owen1, Christine M Komarck1, Anthony C Wang2, Waleed M Abuzeid1, Richard F Keep2, Erin L McKean1, Stephen Sullivan2, Xing Fan2,3, Mark E P Prince1.   

Abstract

OBJECTIVE Chordomas are rare malignant tumors thought to arise from remnants of the notochord. They can be located anywhere along the axial skeleton but are most commonly found in the clival and sacrococcygeal regions, where the notochord regresses during fetal development. Chordomas are resistant to many current therapies, leaving surgery as the primary method of treatment. Cancer cell lines have been useful for developing new cancer treatments in a laboratory setting that can then be transferred to the clinic, but there are only 4 validated chordoma cell lines available. The objective of this work was to establish chordoma cell lines from surgical tissue in order to expand the library of lines available for laboratory research. METHODS Chordoma tissue from the clivus was processed and sorted by flow cytometry to obtain an isolated population of chordoma cells. These cells were grown in culture and expanded until enough doublings to consider the line established. Identification of a chordoma cell line was made with known markers for chordoma, and the line was observed for ALDH (aldehyde dehydrogenase) subpopulations and tested in serum-free growth conditions as well as in vivo. RESULTS A fifth chordoma cell line, UM-Chor1, was successfully established. This is the first chordoma cell line originating from the clivus. Validation was confirmed by phenotype and positivity for the chordoma markers CD24 and brachyury. The authors also attempted to identify an ALDHhigh cell population in UM-Chor1, UCH1, and UCH2 but did not detect a distinct population. UM-Chor1 cells were able to form spheroids in serum-free culture, were successfully transduced with luciferase, and could be injected parasacrally and grown in NOD/SCID mice. CONCLUSIONS The availability of this novel clival chordoma cell line for in vitro and in vivo research provides an opportunity for developments in treatment against the disease.

Entities:  

Keywords:  ALDH = aldehyde dehydrogenase; DAPI = 4′,6-diamidino-2-phenylindole; DEAB = diethylaminobenzaldehyde; EMA = epithelial membrane antigen; FITC = fluorescein isothiocyanate; FSP = fibroblast surface protein; GFP = green fluorescent protein; HBSS = Hank's balanced salt solution; NCAM = neural cell adhesion molecule; PBS = phosphate-buffered saline; PE = phycoerythrin; cell line; chordoma; clivus; oncology; rHIV = recombinant human immunodeficiency virus

Mesh:

Year:  2017        PMID: 28430034      PMCID: PMC5650943          DOI: 10.3171/2016.10.JNS16877

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  40 in total

1.  Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1.

Authors:  Beate Rinner; Elke Verena Froehlich; Karin Buerger; Heike Knausz; Birgit Lohberger; Susanne Scheipl; Carina Fischer; Andreas Leithner; Christian Guelly; Slave Trajanoski; Karoly Szuhai; Bernadette Liegl
Journal:  Int J Oncol       Date:  2011-10-14       Impact factor: 5.650

2.  Characterization of cancer stem-like cells in chordoma.

Authors:  Esra Aydemir; Omer Faruk Bayrak; Fikrettin Sahin; Basar Atalay; Gamze Torun Kose; Mustafa Ozen; Serhat Sevli; Altay Burak Dalan; Mehmet Emir Yalvac; Turgut Dogruluk; Uğur Türe
Journal:  J Neurosurg       Date:  2012-01-27       Impact factor: 5.115

3.  Sacral chordomas: Impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor.

Authors:  Lily Park; Thomas F Delaney; Norbert J Liebsch; Francis J Hornicek; Saveli Goldberg; Henry Mankin; Andrew E Rosenberg; Daniel I Rosenthal; Herman D Suit
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-06       Impact factor: 7.038

4.  Revisiting chordoma with brachyury, a "new age" marker: analysis of a validation study on 51 cases.

Authors:  Nirmala A Jambhekar; Bharat Rekhi; Kiran Thorat; Rajesh Dikshit; Manish Agrawal; Ajay Puri
Journal:  Arch Pathol Lab Med       Date:  2010-08       Impact factor: 5.534

5.  CD24 is expressed specifically in the nucleus pulposus of intervertebral discs.

Authors:  Nobuyuki Fujita; Takeshi Miyamoto; Jun-ichi Imai; Naobumi Hosogane; Toru Suzuki; Mitsuru Yagi; Kozo Morita; Ken Ninomiya; Kana Miyamoto; Hironari Takaishi; Morio Matsumoto; Hideo Morioka; Hiroo Yabe; Kazuhiro Chiba; Shinya Watanabe; Yoshiaki Toyama; Toshio Suda
Journal:  Biochem Biophys Res Commun       Date:  2005-11-10       Impact factor: 3.575

Review 6.  The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract: from research to therapy.

Authors:  Eyal Sagiv; Nadir Arber
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2008-02       Impact factor: 3.869

7.  Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.

Authors:  Fabio Bozzi; Giacomo Manenti; Elena Conca; Silvia Stacchiotti; Antonella Messina; GianPaolo Dagrada; Alessandro Gronchi; Pietro Panizza; Marco A Pierotti; Elena Tamborini; Silvana Pilotti
Journal:  Neuro Oncol       Date:  2014-01       Impact factor: 12.300

8.  Mechanisms of chemoresistance in cancer stem cells.

Authors:  Lissa Nurrul Abdullah; Edward Kai-Hua Chow
Journal:  Clin Transl Med       Date:  2013-01-17

9.  Insights into the hallmarks of human nucleus pulposus cells with particular reference to cell viability, phagocytic potential and long process formation.

Authors:  Yu-Fei Chen; Yong-Zhao Zhang; Wei-Lin Zhang; Guan-Nan Luan; Zhi-Heng Liu; Yang Gao; Zhong-Yuan Wan; Zhen Sun; Shu Zhu; Dino Samartzis; Chun-Mei Wang; Hai-Qiang Wang; Zhuo-Jing Luo
Journal:  Int J Med Sci       Date:  2013-10-31       Impact factor: 3.738

10.  Overexpression of brachyury contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma.

Authors:  Rui Du; Shanshan Wu; Xiaoning Lv; Henghu Fang; Sudong Wu; Jingbo Kang
Journal:  J Exp Clin Cancer Res       Date:  2014-12-14
View more
  6 in total

1.  Combination of PARP inhibitor and temozolomide to suppress chordoma progression.

Authors:  Xiaoyu Cao; Yanxin Lu; Yang Liu; Yiqiang Zhou; Hua Song; Wei Zhang; Dionne Davis; Jing Cui; Shuyu Hao; Jinkyu Jung; Qixin Wu; Deric M Park; Chunzhang Yang
Journal:  J Mol Med (Berl)       Date:  2019-06-14       Impact factor: 4.599

2.  Advancement of PI3 Kinase Inhibitor Combination Therapies for PI3K-Aberrant Chordoma.

Authors:  Molly E Heft Neal; Nicole L Michmerhuizen; Kevin J Kovatch; John Henry J Owen; Jingyi Zhai; Hui Jiang; Erin L McKean; Mark E P Prince; J Chad Brenner
Journal:  J Neurol Surg B Skull Base       Date:  2020-10-12

3.  Inducing substances for chondrogenic differentiation of dental pulp stem cells in the conditioned medium of a novel chordoma cell line.

Authors:  Hiroyoshi Kino; Hiroyoshi Akutsu; Hiroshi Ishikawa; Shingo Takano; Shohei Takaoka; Junko Toyomura; Takuma Hara; Eiichi Ishikawa; Yuji Matsumaru; Hiroki Bukawa; Akira Matsumura
Journal:  Hum Cell       Date:  2022-01-31       Impact factor: 4.174

4.  Combinatorial Natural Killer Cell-based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells.

Authors:  Austin T K Hoke; Michelle R Padget; Kellsye P Fabian; Anjali Nandal; Gary L Gallia; Marijo Bilusic; Patrick Soon-Shiong; James W Hodge; Nyall R London
Journal:  Cancer Res Commun       Date:  2021-12

5.  Computational Drug Repositioning Identifies Potentially Active Therapies for Chordoma.

Authors:  Jeffrey I Traylor; Hadley E Sheppard; Visweswaran Ravikumar; Jonathan Breshears; Shaan M Raza; Charles Y Lin; Shreyaskumar R Patel; Franco DeMonte
Journal:  Neurosurgery       Date:  2021-01-13       Impact factor: 5.315

6.  Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft.

Authors:  Thibault Passeri; Ahmed Dahmani; Julien Masliah-Planchon; Adnan Naguez; Marine Michou; Rania El Botty; Sophie Vacher; Rachida Bouarich; André Nicolas; Marc Polivka; Coralie Franck; Anne Schnitzler; Fariba Némati; Sergio Roman-Roman; Franck Bourdeaut; Homa Adle-Biassette; Hamid Mammar; Sébastien Froelich; Ivan Bièche; Didier Decaudin
Journal:  Cancers (Basel)       Date:  2022-03-14       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.